Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

Plain-language summary

This study evaluates the use of a multi-component liquid biopsy test to identify, monitor and predict recurrence in urothelial carcinoma (a type of bladder/urinary tract cancer). People with suspected or histologically confirmed urothelial carcinoma may take part. This is a study with no assigned phase and it is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Tianjin Medical University Second Hospital

Intervention

Multi-Component Liquid Biopsy for Urothelial Carcinoma

Start date

3/1/2026

Estimated completion

1/1/2029

Countries

China

Related genes

Locations

• Tianjin, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Suspected or histologically confirmed urothelial carcinoma

Exclusion Criteria:

* History of or concurrent active malignancy other than urothelial carcinoma